Heru said it has surpassed 1 million eyes tested on Heru Prime, the company’s wearable diagnostic device that features 11 ocular testing modalities. Heru Prime, registered with the US Food and Drug Administration (FDA), uses AI strategies, developed at Bascom Palmer Eye Institute in Miami, to digitize and automate manual eye tests for a more efficient workflow and clinical consistency, according to a company press release. The result, said Heru, is that physicians can test more patients.
The testing modalities featured include visual acuity, near and far cover testing, Ishihara color vision, quantitative pupillometry, suprathreshold visual field (VF), 24-2 or 10-2 full-threshold VF, Esterman VF, Firefly VF confrontation, and extraocular motility. It provides detailed printouts of results. The platform is backed by more than 60 patents and is clinically validated to replace several legacy diagnostic devices, according to Heru.